Key Inclusion Criteria:

          -  Able to understand and give written informed consent.

          -  Individuals with the following histologically documented metastatic (M1, Stage IV) or
             locally advanced solid tumors. Tumor blocks (preferably, obtained within 12 months of
             study entry if clinically feasible) or 20 newly sectioned slides (6 minimum) of
             archived biopsy/surgical specimens are requested. these specimens should be submitted
             within 28 days before initiating Screening, after the individual provides written
             informed consent. A baseline biopsy is required if archival tissue is not available.
             Fine needle aspirations and bone biopsies are not suitable samples.

               -  Non-small cell lung cancer (NSCLC) (adenocarcinoma or squamous cell carcinoma
                  (SCC)), that has progressed after prior platinum-based chemotherapy and
                  Programmed death-ligand 1 (PD-L1) or Programmed cell death protein 1 (PD-1)
                  directed therapy; recurrence/ relapse or lack of response within 6 months of
                  completion of chemotherapy for locally advanced disease, that line of therapy may
                  be counted for eligibility.

               -  Incurable, recurrent, or metastatic HNSCC that has progressed after prior
                  platinum based chemotherapy and PD-LI or PD-1 directed therapy

               -  Relapsed unresectable endometrial cancer that has progressed after prior platinum
                  based chemotherapy or is refractory to platinum based chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1

          -  Adequate hematologic counts without transfusional or growth factor support within 2
             weeks of study drug initiation

          -  Adequate hepatic function

          -  Individual must have at least a 3-month life expectancy

          -  Have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging
             (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Tumor
             lesions situated in a previously irradiated area may be utilized if they are
             considered measurable and progression has been demonstrated in such lesions.

        Key Exclusion Criteria:

          -  Have had a prior anti-cancer biologic agent within 4 weeks prior to study Day 1 or
             have had prior chemotherapy, targeted small molecule therapy, radiation therapy within
             2 weeks prior to Study Day 1

          -  Have not recovered (i.e., ≤ Grade 1) from adverse events due to a previously
             administered agent

          -  Have previously received topoisomerase I inhibitors

          -  Have an active second malignancy

          -  Have known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Individuals with previously treated brain metastases may participate
             provided they have stable CNS disease for at least 4 weeks prior to the first dose of
             study drug and all neurologic symptoms have returned to baseline, have no evidence of
             new or enlarging brain metastases and are taking ≤20 mg/day of prednisone or its
             equivalent. All individuals with carcinomatous meningitis are excluded regardless of
             clinical stability

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.